Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HITPhase 2 data showed a greater than 25% absolute reduction ...